RESPONDER-HF Trial

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 750 participants.

Also called NCT05425459

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 750 participants (planned count) (from the registry)
Sponsor
Corvia Medical (from the registry)
Registry
  • NCT NCT05425459
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Austria, Belgium, Canada, Germany, Netherlands (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05425459. Randomized; triple masking; primary purpose treatment. Start 2022-11-17 (actual); primary completion 2027-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
RESPONDER-HF Trial
Condition
Heart Failure
Condition
Heart Failure, Diastolic
Intervention (Device)
Corvia Atrial Shunt System / IASD System II
Intervention (Other)
Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)
Lead sponsor
Corvia Medical (class: industry)

Record details

Record id
cardio:ct-nct05425459
Content hash
5299fe6bffc26b747c8a9ce49b1cc3c225a7d6d351072322b234360e7c9b902c